What does AGC stand for?

Trastuzumab, in combination with standard cisplatin-based chemotherapy, is well tolerated and provides significant survival benefits over chemotherapy alone for patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer, researchers stated at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO).

Experts at ASCO agreed that all patients with advanced gastric cancer should be tested for HER2, and if found to be positive should be treated with trastuzumab in addition to their usual chemotherapy.

Nimotuzumab - Anti-EGFR Monoclonal Antibody (this is their most advanced drug) Late-stage development, early stage commercialization - approved in 10 countries, in pivotal trials in Europe and other territories YM has rights for North America, Europe, Japan, Korea and, Australasia In Japan and Korea alone, advanced gastric cancer is a >$800mm market European Union would translate into >$700mm Nimotuzumab has been in over 3,000 patients and in more than 30 clinical trials in more than 10 tumour types.

Efficacy results from the ToGA trial: a Phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC).

However, the prognosis for patients with locally advanced gastric cancer remains poor, even after potentially curative resection, with a high risk of locoregional and/or distant recurrence, which occurs in almost 60% of patients who undergo R0 resection [1-3].

The goal of any treatment in patients affected with advanced gastric cancer (AGC) is palliation of symptoms related to disease, improving or maintaining performance status (PS) and quality of life (QoL), and when possible to prolong survival.

Randomized controlled trial of adjuvant uracil-tegafur versus surgery alone for serosa-negative, locally advanced gastric cancer.

Tesetaxel has demonstrated anticancer activity in several completed Phase 2 clinical trials, including patients with advanced gastric cancer and advanced breast cancer.